Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira in Patients With Moderate to Severe Active Rheumatoid Arthritis

Next Previous
Trial Profile

A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira in Patients With Moderate to Severe Active Rheumatoid Arthritis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms ADMYRA
  • Sponsors HEXAL; Sandoz

Most Recent Events

  • 30 Jan 2023 According to Sandoz media release, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive opinion for marketing authorization for a citrate-free high concentration formulation of adalimumab. The authorization includes all indications covered by the reference medicine: rheumatoid arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis and uvetis.
  • 09 Nov 2021 Results of a pooled analysis of data from 4 phase I studies (study 101,102, 103 & 104) and 2 phase III studies (ADACCESS & ADMYRA) presented at the ACR Convergence 2021
  • 05 Jun 2021 Results of a pooled analysis of data from 4 phase I studies (study 101,102, 103 & 104) and 2 phase III studies (ADACCESS & ADMYRA) assessing the local tolerance to formulations containing citrate bufferpresented at the 22nd Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top